Shenzhen Genoimmune Medical Institute

Shenzhen Geno-Immune Medical Institute Ranked Top 2 Globally! Top 10 R&D Institutions for Immune Cell Therapy Products in 2024 Revealed – The US and China Dominate 95% of All Clinical Trials

How many CAR-T infusions are needed for solid tumors？

In the past decade, the US FDA has approved many tumor immunotherapy products

ASGCT 2020 Abstract：Safety Evaluation of Intracerebral Injection of LentiviralABCD1 for X-ALD Gene Therapy

ASGCT 2020 Abstract：Lentiviral Gene Therapy for Hemophilia B: Exploration of Endothelial Promoters in Mesenchymal Stem Cells

ASGCT 2020 Abstract：Lentiviral Gene Therapy of Hemophilia A: Expression and Functional Comparison of Universal and Tissue-specific Promoters

The COVID-19 vaccine development landscape

Dr. Lung Ji-Chang, President of Shenzhen Genoimmune Medical Institute, in the signing ceremony of the Memorandum of Understanding (MoU) for “Technology Transfer and Application on CAR-T and Gene Therapy” at the Faculty of Medicine Siriraj Hospital

Global CAR T-Cell Therapy Market Analysis Report

The "Global CAR T-Cell Therapy Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

GIMI 2019 GTCA

GIMI 2019 GTCA International Medical Conference will be held during 20-21 April 2019 in Shenzhen, China.